Literature DB >> 33664492

Transcriptional mediators of treatment resistance in lethal prostate cancer.

Meng Xiao He1,2,3, Michael S Cuoco3, Jett Crowdis2,3, Alice Bosma-Moody2,3,4, Zhenwei Zhang2,5, Kevin Bi2,3, Abhay Kanodia2, Mei-Ju Su2, Sheng-Yu Ku2, Maria Mica Garcia2, Amalia R Sweet6, Christopher Rodman3, Laura DelloStritto2,7, Rebecca Silver2, John Steinharter2, Parin Shah2, Benjamin Izar8,9, Nathan C Walk2, Kelly P Burke2,10,11, Ziad Bakouny2, Alok K Tewari2, David Liu2,3, Sabrina Y Camp2,3, Natalie I Vokes2,3,12,13, Keyan Salari3,14, Jihye Park2,3, Sébastien Vigneau2,3,7, Lawrence Fong15, Joshua W Russo6, Xin Yuan6, Steven P Balk6, Himisha Beltran2, Orit Rozenblatt-Rosen3, Aviv Regev3,16,17, Asaf Rotem2,3,7,18, Mary-Ellen Taplin2, Eliezer M Van Allen19,20,21.   

Abstract

Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors1. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites. Irrespective of treatment exposure, adenocarcinoma cells pervasively coexpressed multiple androgen receptor isoforms, including truncated isoforms hypothesized to mediate resistance to androgen-targeting therapies2,3. Resistance to enzalutamide was associated with cancer cell-intrinsic epithelial-mesenchymal transition and transforming growth factor-β signaling. Small cell carcinoma cells exhibited divergent expression programs driven by transcriptional regulators promoting lineage plasticity and HOXB5, HOXB6 and NR1D2 (refs. 4-6). Additionally, a subset of patients had high expression of dysfunction markers on cytotoxic CD8+ T cells undergoing clonal expansion following enzalutamide treatment. Collectively, the transcriptional characterization of cancer and immune cells from human metastatic castration-resistant prostate cancer provides a basis for the development of therapeutic approaches complementing androgen signaling inhibition.

Entities:  

Year:  2021        PMID： 33664492      PMCID： PMC7960507          DOI： 10.1038/s41591-021-01244-6

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  46 in total

Review 1.  Are androgen receptor variants a substitute for the full-length receptor?

Authors:  Ji Lu; Travis Van der Steen; Donald J Tindall
Journal:  Nat Rev Urol       Date:  2015-02-10       Impact factor: 14.432

Review 2.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

3.  Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.

Authors:  William S Chen; Rahul Aggarwal; Li Zhang; Shuang G Zhao; George V Thomas; Tomasz M Beer; David A Quigley; Adam Foye; Denise Playdle; Jiaoti Huang; Paul Lloyd; Eric Lu; Duanchen Sun; Xiangnan Guan; Matthew Rettig; Martin Gleave; Christopher P Evans; Jack Youngren; Lawrence True; Primo Lara; Vishal Kothari; Zheng Xia; Kim N Chi; Robert E Reiter; Christopher A Maher; Felix Y Feng; Eric J Small; Joshi J Alumkal
Journal:  Eur Urol       Date:  2019-03-28       Impact factor: 20.096

4.  Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

Authors:  Matti Annala; Gillian Vandekerkhove; Daniel Khalaf; Sinja Taavitsainen; Kevin Beja; Evan W Warner; Katherine Sunderland; Christian Kollmannsberger; Bernhard J Eigl; Daygen Finch; Conrad D Oja; Joanna Vergidis; Muhammad Zulfiqar; Arun A Azad; Matti Nykter; Martin E Gleave; Alexander W Wyatt; Kim N Chi
Journal:  Cancer Discov       Date:  2018-01-24       Impact factor: 39.397

5.  A new abnormal haemoglobin--haemoglobin Singapore, alpha 2-141 Pro beta 2.

Authors:  W H Boon
Journal:  J Singapore Paediatr Soc       Date:  1969-10

6.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

Review 7.  Treatment of Advanced Prostate Cancer.

Authors:  Min Yuen Teo; Dana E Rathkopf; Philip Kantoff
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

8.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.

Authors:  Ping Mu; Zeda Zhang; Matteo Benelli; Wouter R Karthaus; Elizabeth Hoover; Chi-Chao Chen; John Wongvipat; Sheng-Yu Ku; Dong Gao; Zhen Cao; Neel Shah; Elizabeth J Adams; Wassim Abida; Philip A Watson; Davide Prandi; Chun-Hao Huang; Elisa de Stanchina; Scott W Lowe; Leigh Ellis; Himisha Beltran; Mark A Rubin; David W Goodrich; Francesca Demichelis; Charles L Sawyers
Journal:  Science       Date:  2017-01-06       Impact factor: 47.728

9.  Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.

Authors:  Gisely T Borges; Eneida F Vêncio; Sue-Ing Quek; Adeline Chen; Diego M Salvanha; Ricardo Z N Vêncio; Holly M Nguyen; Robert L Vessella; Christopher Cavanaugh; Carol B Ware; Pamela Troisch; Alvin Y Liu
Journal:  J Cell Physiol       Date:  2016-02-04       Impact factor: 6.384

10.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Authors:  Alexander W Wyatt; Arun A Azad; Stanislav V Volik; Matti Annala; Kevin Beja; Brian McConeghy; Anne Haegert; Evan W Warner; Fan Mo; Sonal Brahmbhatt; Robert Shukin; Stephane Le Bihan; Martin E Gleave; Matti Nykter; Colin C Collins; Kim N Chi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777
View more
  25 in total

1.  Signature-scoring methods developed for bulk samples are not adequate for cancer single-cell RNA sequencing data.

Authors:  Nighat Noureen; Zhenqing Ye; Yidong Chen; Xiaojing Wang; Siyuan Zheng
Journal:  Elife       Date:  2022-02-25       Impact factor: 8.140

2.  Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.

Authors:  Youmna Kfoury; Ninib Baryawno; Nicolas Severe; Shenglin Mei; Karin Gustafsson; Taghreed Hirz; Thomas Brouse; Elizabeth W Scadden; Anna A Igolkina; Konstantinos Kokkaliaris; Bryan D Choi; Nikolas Barkas; Mark A Randolph; John H Shin; Philip J Saylor; David T Scadden; David B Sykes; Peter V Kharchenko
Journal:  Cancer Cell       Date:  2021-10-15       Impact factor: 31.743

Review 3.  Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.

Authors:  Andrea K Miyahira; Jelani C Zarif; Catherine C Coombs; Robert R Flavell; Joshua W Russo; Samir Zaidi; Di Zhao; Shuang G Zhao; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2021-11-03       Impact factor: 4.104

4.  Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.

Authors:  Johann S de Bono; Adam Sharp; Adam G Sowalsky; Ines Figueiredo; Rosina T Lis; Ilsa Coleman; Bora Gurel; Denisa Bogdan; Wei Yuan; Joshua W Russo; John R Bright; Nichelle C Whitlock; Shana Y Trostel; Anson T Ku; Radhika A Patel; Lawrence D True; Jonathan Welti; Juan M Jimenez-Vacas; Daniel Nava Rodrigues; Ruth Riisnaes; Antje Neeb; Cynthia T Sprenger; Amanda Swain; Scott Wilkinson; Fatima Karzai; William L Dahut; Steven P Balk; Eva Corey; Peter S Nelson; Michael C Haffner; Stephen R Plymate
Journal:  Clin Cancer Res       Date:  2022-08-15       Impact factor: 13.801

5.  Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.

Authors:  Julia Schiantarelli; Theodora Pappa; Jake Conway; Jett Crowdis; Brendan Reardon; Felix Dietlein; Julian Huang; Darren Stanizzi; Evan Carey; Alice Bosma-Moody; Alma Imamovic; Seunghun Han; Sabrina Camp; Eric Kofman; Erin Shannon; Justine A Barletta; Meng Xiao He; David Liu; Jihye Park; Jochen H Lorch; Eliezer M Van Allen
Journal:  JCO Precis Oncol       Date:  2022-08

6.  Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Fen Ma; Seiji Arai; Keshan Wang; Carla Calagua; Amanda R Yuan; Larysa Poluben; Zhongkai Gu; Joshua W Russo; David J Einstein; Huihui Ye; Meng Xiao He; Yu Liu; Eliezer Van Allen; Adam G Sowalsky; Manoj K Bhasin; Xin Yuan; Steven P Balk
Journal:  Cancer Res       Date:  2022-04-15       Impact factor: 13.312

7.  Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.

Authors:  Kevin Bi; Meng Xiao He; Ziad Bakouny; Abhay Kanodia; Sara Napolitano; Jingyi Wu; Grace Grimaldi; David A Braun; Michael S Cuoco; Angie Mayorga; Laura DelloStritto; Gabrielle Bouchard; John Steinharter; Alok K Tewari; Natalie I Vokes; Erin Shannon; Maxine Sun; Jihye Park; Steven L Chang; Bradley A McGregor; Rizwan Haq; Thomas Denize; Sabina Signoretti; Jennifer L Guerriero; Sébastien Vigneau; Orit Rozenblatt-Rosen; Asaf Rotem; Aviv Regev; Toni K Choueiri; Eliezer M Van Allen
Journal:  Cancer Cell       Date:  2021-03-11       Impact factor: 31.743

8.  Androgen receptor activity in T cells limits checkpoint blockade efficacy.

Authors:  Xiangnan Guan; Fanny Polesso; Chaojie Wang; Archana Sehrawat; Reed M Hawkins; Susan E Murray; George V Thomas; Breanna Caruso; Reid F Thompson; Mary A Wood; Christina Hipfinger; Scott A Hammond; Julie N Graff; Zheng Xia; Amy E Moran
Journal:  Nature       Date:  2022-03-23       Impact factor: 69.504

9.  Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.

Authors:  Qing Cheng; William Butler; Yinglu Zhou; Hong Zhang; Lu Tang; Kathryn Perkinson; Xufeng Chen; Xiaoyin Sara Jiang; Shannon J McCall; Brant A Inman; Jiaoti Huang
Journal:  Eur Urol       Date:  2022-01-17       Impact factor: 24.267

Review 10.  Therapy considerations in neuroendocrine prostate cancer: what next?

Authors:  Himisha Beltran; Francesca Demichelis
Journal:  Endocr Relat Cancer       Date:  2021-07-15       Impact factor: 5.900
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.